Motus GI (MOTS) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 11, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38389
Entity Registrant Name	Motus GI Holdings, Inc.
Entity Central Index Key	0001686850
Entity Tax Identification Number	81-4042793
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1301 East Broward Boulevard
Entity Address, Address Line Two	3rd Floor
Entity Address, City or Town	Ft. Lauderdale
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33301
City Area Code	(954)
Local Phone Number	541 8000
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	MOTS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,655,596

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 13,294	$ 22,563
Accounts receivable	161	109
Inventory	1,014	496
Prepaid expenses and other current assets	1,018	793
Total current assets	15,487	23,961
Fixed assets, net	1,395	1,428
Right-of-use assets	471	687
Other non-current assets	13	13
Total assets	17,366	26,089
Current liabilities:
Accounts payable and accrued expenses	2,696	2,584
Operating lease liabilities - current	248	307
Other current liabilities	70	10
Current portion of long-term debt, net of unamortized debt discount of $260 and $271, respectively	2,453	431
Total current liabilities	5,467	3,332
Contingent royalty obligation	1,789	1,760
Operating lease liabilities - non-current	220	385
Convertible note, net of unamortized debt discount of $123 and $166, respectively	3,877	3,834
Long-term debt, net of unamortized debt discount of $176 and $317, respectively	5,251	7,121
Total liabilities	16,604	16,432
Commitments and contingent liabilities (Note 9)
Shareholders’ equity
Common stock $0.0001 par value; 115,000,000 shares authorized; 3,025,502 and 2,416,021 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively
Additional paid-in capital	138,431	132,411
Accumulated deficit	(137,669)	(122,754)
Total shareholders’ equity	762	9,657
Total liabilities and shareholders’ equity	$ 17,366	$ 26,089

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Debt instrument, unamortized discount	$ 260	$ 271
Convertible note, unamortized discount, noncurrent	123	166
Debt instrument, unamortized discount, non-current	$ 176	$ 317
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	115,000,000	115,000,000
Common stock, shares issued	3,025,502	2,416,021
Common stock, shares outstanding	3,025,502	2,416,021

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue	$ 278	$ 141	$ 483	$ 292
Operating expenses:
Cost of revenue - sales	83	65	166	135
Cost of revenue - impairment of inventory		186	159	186
Research and development	1,573	1,187	4,261	4,040
Sales and marketing	1,349	725	3,554	2,196
General and administrative	1,978	2,315	6,167	7,104
Total costs and expenses	4,983	4,478	14,307	13,661
Operating loss	(4,705)	(4,337)	(13,824)	(13,369)
Gain (loss) on change in estimated fair value of contingent royalty obligation	34	(35)	(29)	(152)
Loss on extinguishment of debt		(237)		(237)
Finance expense, net	(310)	(216)	(1,001)	(450)
Other income		5		5
Foreign currency gain (loss)	17	(4)	(61)	(12)
Net loss	(4,964)	(4,824)	(14,915)	(14,215)
Deemed dividends from warrant issuance				(6,145)
Net loss attributable to common shareholders	$ (4,964)	$ (4,824)	$ (14,915)	$ (20,360)
Basic and diluted loss per common share:
Net loss attributable to common shareholders	$ (1.69)	$ (2)	$ (5.40)	$ (8.77)
Weighted average number of common shares outstanding, basic and diluted	2,937,530	2,412,059	2,763,164	2,320,982

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020		$ 115,011	$ (103,721)	$ 11,290
Beginning balance, shares at Dec. 31, 2020	1,613,591
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units, shares	3,295
Issuance of common stock for board of directors’ compensation		272		272
Issuance of common stock for board of directors' compensation, shares	8,677
Share based compensation		919		919
Net loss			(4,649)	(4,649)
Issuance of common shares upon exercise of warrants, net of financing costs of $366		11,593		11,593
Issuance of common shares upon exercise of warrant, shares	713,362
Ending balance, value at Mar. 31, 2021		127,795	(108,370)	19,425
Ending balance, shares at Mar. 31, 2021	2,338,925
Beginning balance, value at Dec. 31, 2020		115,011	(103,721)	11,290
Beginning balance, shares at Dec. 31, 2020	1,613,591
Net loss				(14,215)
Ending balance, value at Sep. 30, 2021		131,716	(117,936)	13,780
Ending balance, shares at Sep. 30, 2021	2,412,032
Beginning balance, value at Mar. 31, 2021		127,795	(108,370)	19,425
Beginning balance, shares at Mar. 31, 2021	2,338,925
Issuance of common shares, net of issuance costs of $74		1,826		1,826
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs, shares	67,043
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units, shares	2,654
Issuance of common stock for board of directors’ compensation		19		19
Issuance of common stock for board of directors' compensation, shares	910
Share based compensation		1,010		1,010
Net loss			(4,742)	(4,742)
Issuance of common stock to consultants		53		53
Issuance of common stock to consultants, shares	2,500
Ending balance, value at Jun. 30, 2021		130,703	(113,112)	17,591
Ending balance, shares at Jun. 30, 2021	2,412,032
Share based compensation		848		848
Net loss			(4,824)	(4,824)
Issuance of warrants associated with convertible note and long-term debt		165		165
Ending balance, value at Sep. 30, 2021		131,716	(117,936)	13,780
Ending balance, shares at Sep. 30, 2021	2,412,032
Beginning balance, value at Dec. 31, 2021		132,411	(122,754)	9,657
Beginning balance, shares at Dec. 31, 2021	2,416,021
Issuance of common shares, net of issuance costs of $74		3,004		3,004
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs, shares	298,761
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units, shares	13,721
Issuance of common stock for board of directors’ compensation		235		235
Issuance of common stock for board of directors' compensation, shares	24,458
Share based compensation		521		521
Net loss			(4,811)	(4,811)
Ending balance, value at Mar. 31, 2022		136,171	(127,565)	8,606
Ending balance, shares at Mar. 31, 2022	2,752,961
Beginning balance, value at Dec. 31, 2021		132,411	(122,754)	9,657
Beginning balance, shares at Dec. 31, 2021	2,416,021
Net loss				(14,915)
Ending balance, value at Sep. 30, 2022		138,431	(137,669)	762
Ending balance, shares at Sep. 30, 2022	3,025,502
Beginning balance, value at Mar. 31, 2022		136,171	(127,565)	8,606
Beginning balance, shares at Mar. 31, 2022	2,752,961
Issuance of common shares, net of issuance costs of $74		45		45
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs, shares	8,124
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units, shares	4,174
Share based compensation		461		461
Net loss			(5,140)	(5,140)
Ending balance, value at Jun. 30, 2022		136,677	(132,705)	3,972
Ending balance, shares at Jun. 30, 2022	2,765,259
Issuance of common shares, net of issuance costs of $74		1,324		1,324
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs, shares	258,127
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units, shares	4,162
Share based compensation		441		441
Net loss			(4,964)	(4,964)
Fractional shares settled in cash pursuant to reverse stock split		(11)		(11)
Fractional shares settled in cash pursuant to reverse stock split, shares	(2,046)
Ending balance, value at Sep. 30, 2022		$ 138,431	$ (137,669)	$ 762
Ending balance, shares at Sep. 30, 2022	3,025,502

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]
Payments of financing costs	$ 74	$ 366

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (14,915)	$ (14,215)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	381	318
Amortization of debt issuance costs	195	32
Loss on change in estimated fair value of contingent royalty obligation	29	152
Share based compensation	1,423	2,777
Issuance of common stock for board of directors’ compensation	177	174
Issuance of common stock for consultants		53
Loss on extinguishment of debt		237
Impairment of inventory	159	186
Impairment of fixed assets	46
Amortization on operating lease right-of-use asset	253	152
Changes in operating assets and liabilities:
Accounts receivable	(52)	(146)
Inventory	(843)	48
Prepaid expenses and other current assets	(167)	(97)
Accounts payable and accrued expenses	79	38
Operating lease liabilities - current and non-current	(255)	(163)
Other current liabilities	61	(51)
Net cash used in operating activities	(13,429)	(10,505)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(215)	(425)
Net cash used in investing activities	(215)	(425)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common shares	4,544	1,900
Fractional shares paid in cash pursuant to reverse stock split	(11)
Proceeds from exercise and purchase of warrants		11,959
Borrowings under convertible note and long-term debt		9,000
Repayment of term debt		(8,220)
Payment of debt issuance costs		(437)
Equity financing fees	(158)	(439)
Net cash provided by financing activities	4,375	13,763
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(9,269)	2,833
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	22,563	20,819
CASH AND CASH EQUIVALENTS AT END OF PERIOD	13,294	23,652
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest	779	443
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued to settle accrued expenses for board of directors’ compensation		56
Common stock issued for prepaid board of directors’ compensation	58	61
Reclassification of inventory to fixed assets	163	56
Reclassification of prepaid expenses to fixed assets	4	75
Purchase of fixed assets in accounts payable and accrued expenses	12	22
Financing costs included in accounts payable and accrued expenses	13
Warrants issued related to convertible note and long-term debt recorded as debt discount		165
Accrued end of loan payment recorded as debt discount		88
Operating lease liabilities arising from obtaining right-of-use assets	$ 3	$ 135

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1 – Description of Business Motus GI Holdings, Inc. (the “Company”) was incorporated in Delaware, U.S.A. in September 2016. The Company and its subsidiaries, Motus GI Technologies, Ltd. and Motus GI, LLC, are collectively referred to as “Motus GI” or the “Company”. The Company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the “FDA”) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (“GI”) endoscopy procedures. The Pure-Vu System has received a CE Mark in the EU for use in colonoscopy. The Pure-Vu System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during colonoscopy and upper GI procedures while preserving established procedural workflow and techniques. Through irrigation and evacuation of debris, the Pure-Vu System is designed to provide better-quality exams. The Company received 510(k) clearance in February 2022 from the FDA for its Pure-Vu EVS System and recently commenced commercialization of this product.

Basis of Presentation and Going

Basis of Presentation and Going Concern	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Going Concern	Note 2 – Basis of Presentation and Going Concern The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the 2021 10-K filed with the SEC on March 29, 2022. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information, the instructions for Form 10-Q and the rules and regulations of the SEC. Accordingly, since they are interim statements, the accompanying condensed consolidated financial statements do not include all of the information and notes required by GAAP for annual financial statements, but reflect all adjustments consisting of normal, recurring adjustments, that are necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of the results that may be expected for any future periods. The December 31, 2021 balance sheet information was derived from the audited financial statements as of that date. To date, the Company has generated minimal revenues, experienced negative operating cash flows and has incurred substantial operating losses from its activities. Management expects the Company to continue to generate substantial operating losses and to continue to fund its operations primarily through utilization of its current financial resources, future product sales, and through the issuance of debt or equity. Rising inflation and financial market volatility may adversely impact the Company’s ability to enter into, modify, and negotiate favorable terms and conditions relative to equity and debt financing initiatives. The uncertain financial markets, potential disruptions in supply chains, and changing priorities could also affect the Company’s ability to enter into key agreements. COVID-19 and government measures taken in response have also had an impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as certain medical services and supplies, have spiked, while demand for other goods and services have fallen. The future progression of the outbreak and its longer-term effects on the Company’s business and operations continue to evolve and are still uncertain. The Company and its third-party contract manufacturers, contract research organizations, and clinical sites may also face disruptions in procuring items that are essential to the Company’s research and development activities, including, for example, medical and laboratory supplies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts related to the outbreak in certain parts of the world. These disruptions may negatively impact the Company’s sales, its results of operations, financial condition, and liquidity in 2022 and into 2023. The Company has financed its operations primarily through sales of equity-related securities. In March 2021, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer”), under which we may offer and sell from time to time common shares having an aggregate offering price of up to $ 25.0 565 4.4 0.2 1.6 5.5 0.2 Net cash used in operating activities for the nine months ended September 30, 2022 was $ 13,429 14,915 13,294 Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Significant Accounting Policies The significant accounting policies used in preparation of these condensed consolidated financial statements for the nine months ended September 30, 2022 are consistent with those discussed in Note 3 to the consolidated financial statements in the Company’s 2021 Annual Report on Form 10-K. There have been no material changes to the Company’s significant accounting policies during the nine months ended September 30, 2022. Reverse Stock Split On July 25, 2022, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-20. Shares of common stock underlying outstanding stock options and other equity instruments convertible into common stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. Accordingly, all share and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split. Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and include the accounts of the Company and its wholly owned subsidiaries, Motus Ltd., an Israel corporation, which has operations in Tirat Carmel, Israel, and Motus Inc., a Delaware corporation, which has operations in the U.S. All inter-company accounts and transactions have been eliminated in consolidation. Use of estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Basic and diluted net loss per share Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year. Diluted loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive ordinary shares had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”. Potentially dilutive common shares were excluded from the calculation of diluted loss per share for all periods presented due to their anti-dilutive effect due to losses in each period. Net loss attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed preferred stock dividends declared, amortized or accumulated. The Company recorded a deemed dividend for the issuance of warrants during the three and nine months ended September 30, 2021 of $ 0 6,145 Income taxes The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of September 30, 2022 and December 31, 2021, the Company had a full valuation allowance against its deferred tax assets. For the three and nine months ended September 30, 2022 and 2021, the Company recorded zero income tax expense. No tax benefit has been recorded in relation to the pre-tax loss for the three and nine months ended September 30, 2022 and 2021, due to a full valuation allowance to offset any deferred tax asset related to net operating loss carry forwards attributable to the losses. New Accounting Pronouncements- Recently Adopted In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50) Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options Accounting Pronouncements- Not Yet Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. In September 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for the Company to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company will continue to evaluate the effect of adopting ASU 2016-13 on the Company’s financial statements and disclosures.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4 – Fair Value Measurements Liabilities measured and recorded at fair value on a recurring basis consisted of the following at September 30, 2022 and December 31, 2021: Schedule of Fair Value of Financial Assets and Liabilities September 30, 2022 Level 1 Level 2 Level 3 Fair Value Liabilities Contingent royalty obligation $ - $ - $ 1,789 $ 1,789 December 31, 2021 Level 1 Level 2 Level 3 Fair Value Liabilities Contingent royalty obligation $ - $ - $ 1,760 $ 1,760 Financial instruments with carrying values approximating fair value include cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses, and certain other current liabilities, due to their short-term nature. In estimating the fair value of the Company’s contingent royalty obligation (see Note 9), the Company used the discounted cash flow method as of September 30, 2022 and December 31, 2021. Based on the fair value hierarchy, the Company classified contingent royalty obligation within Level 3 because valuation inputs are based on projected revenues discounted to a present value. Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of a contingent royalty obligation, during the nine months ended September 30, 2022 was as follows: Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation Fair Value Measurements of Contingent Royalty Obligation (Level 3) Balance at December 31, 2021 $ 1,760 Change in estimated fair value of contingent royalty obligation 29 Balance at September 30, 2022 $ 1,789 The contingent royalty obligation is re-measured at each balance sheet date using several assumptions, including the following: 1) estimated sales growth, 2) length of product cycle, 3) patent life, 4) discount rate ( 23 21 3 In accordance with ASC-820-10-50-2(g), the Company performed a sensitivity analysis of the liability, which was classified as a Level 3 financial instrument. The Company recalculated the fair value of the liability by applying a +/- 2% change to the input variable in the discounted cash flow model; the discount rate. A 2% decrease in the discount rate would increase the liability by $130 and a 2% increase in the discount rate would decrease the liability by $119

Inventory

Inventory	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventory	Note 5 – Inventory Inventory is stated at lower of cost or net realizable value using the weighted average cost method and is evaluated at least annually for impairment. Write-downs for potentially obsolete or excess inventory are made based on management’s analysis of inventory levels, historical obsolescence and future sales forecasts. For the three and nine months ended, September 30, 2022, an inventory impairment of $ 0 159 186 Inventory at September 30, 2022 and December 31, 2021 consisted of the following: Schedule of Inventory September 30, 2022 December 31, 2021 Raw materials $ 194 $ 569 Work-in-process 120 - Finished goods 745 292 Inventory reserve (45 ) (365 ) Inventory, net $ 1,014 $ 496

Fixed assets, net

Fixed assets, net	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Fixed assets, net	Note 6 – Fixed assets, net Fixed assets, summarized by major category, consist of the following for the years ended: Schedule of Fixed Assets Net September 30, 2022 December 31, 2021 Office equipment $ 171 $ 171 Computers and software 319 305 Machinery 1,035 807 Lab and medical equipment 1,439 1,342 Leasehold improvements 195 193 Total 3,159 2,818 Less: accumulated depreciation and amortization (1,764 ) (1,390 ) Fixed assets, net $ 1,395 $ 1,428 Depreciation and amortization expense for the three and nine months ended September 30, 2022 was $ 128 381 10 46 118 318

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases
Leases	Note 7 – Leases The Company leases an office in Fort Lauderdale, Florida under an operating lease. The term expires November 2024. The annual base rent is subject to annual increases of 2.75% The Company leases an office in Israel under an operating lease. The term expires on December 31, 2022 The Company leases vehicles under operating leases that expire at various dates through 2024. Many of these leases provide for payment by the Company, as the lessee, of taxes, insurance premiums, costs of maintenance and other costs which are expenses as incurred. Certain operating leases include escalation clauses and some of which may include options to extend the leases for up to 3 years The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows: Schedule of Lease Cost and Supplemental Balance Sheet Information 2022 2021 2022 2021 Three Months ended September 30, Nine Months ended September 30, 2022 2021 2022 2021 Lease Cost Operating lease cost, net of related party license fee $ 16 $ 36 $ 78 $ 100 Variable lease cost 30 30 90 90 Total lease cost $ 46 $ 66 $ 168 $ 190 As of September 30, As of December 31, 2022 2021 Assets Operating lease, right-of-use-asset $ 471 $ 687 Liabilities Current Operating lease liabilities $ 248 $ 307 Non-current Operating lease liabilities, net of current portion 220 385 Total lease liabilities $ 468 $ 692 Other information: Weighted average remaining lease term - operating leases 1.90 2.49 Weighted-average discount rate - operating leases 7.46 % 7.66 % The Company records operating lease payments to lease expense using the straight-line method. The Company’s lease expense was $ 46 168 66 173 66 190 47 141

Convertible Note and Long-Term

Convertible Note and Long-Term Debt	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Convertible Note and Long-Term Debt	Note 8 – Convertible Note and Long-Term Debt On July 16, 2021 (the “Effective Date”), the Company entered into a loan facility (the “Kreos Loan Agreement”) with Kreos Capital VI (Expert Fund) LP (the “Lender”). Under the Kreos Loan Agreement, the Lender will provide the Company with access to term loans in an aggregate principal amount of up to $ 12,000 4,000 5,000 3,000 The Convertible Note and Tranche B were funded on the Effective Date. As of December 31, 2021 , the Company drew down the full $ 3,000 The Convertible Note requires forty-eight monthly interest only payments at 7.75 28 7.75 In connection with the Kreos Loan Agreement, the Company also issued to the Lender a warrant (“Warrant”), dated July 16, 2021, to purchase up to 9,547 20.948 The Company treated Tranche A, Tranche B and Tranche C, and the Warrant as three separate freestanding financial instruments with the proceeds received in connection with the transaction allocated amongst the instruments based on relative fair value. The proceeds received in connection with the transaction allocated amongst the instruments based on relative fair value resulted in $ 165 845 165 540 274 There is also an end of loan payment of $ 140 845 For the nine months ended September 30 , 2022, interest expense for the Loan was as follows: Schedule of Interest Expense for Loan Contractual interest expense $ 803 Amortization of debt issuance costs 195 Total interest expense $ 998 For the three months ended September 30 , 2022, interest expense for the Loan was as follows: Contractual interest expense $ 268 Amortization of debt issuance costs 70 Total interest expense $ 338 Future principal payments under the Convertible Note as of September 30, 2022 are as follows: Schedule of Future Principal Payments Years Ending December 31, Amount 2022 $ - 2023 - 2024 - 2025 4,000 Total future principal payments 4,000 Less unamortized debt issuance costs (123 ) Total balance $ 3,877 Future principal payments under the Long-term Debt as of September 30, 2022 are as follows: Years Ending December 31, Amount 2022 $ 702 2023 2,714 2024 2,983 2025 1,601 Total future principal payments 8,000 End of loan payments 140 Less unamortized debt issuance costs (436 ) Total term-debt balance $ 7,704 Less current portion of long-term debt (2,453 ) Total long-term debt $ 5,251

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 – Commitments and Contingencies Royalties to the IIA The Company has received grants from the Government of the State of Israel through the Israeli National Authority for Technical Innovation (the “IIA”) for the financing of a portion of its research and development expenditures. The total amount that was received and recorded between the periods ending December 31, 2011 through 2016 was $ 1,332 No 1,426 1,419 4% Repayment of the grants is contingent upon the successful completion of the Company’s R&D programs and generating sales. The Company has no obligation to repay these grants if the R&D program fails, is unsuccessful, or aborted, or if no sales are generated. The Company has recorded an immaterial expense for the three and nine months ended September 30, 2022 and 2021, and an immaterial liability as of September 30, 2022 and December 31, 2021. Royalty Payment Rights on Royalty Payment Rights Certificates The Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”), establishing the rights and preferences of the holders of the Series A Convertible Preferred Stock, including certain directors and officers of the Company (the “Royalty Payment Rights”). As set forth in the Certificate of Designation, the Royalty Payment Rights initially entitled the holders in aggregate, to a royalty in an amount of ● 3% ● 5% In addition, in connection with completion of the 2017 Private Placement, the Company issued the placement agent royalty payment rights certificates (the “Placement Agent Royalty Payment Rights Certificates”) which grants the placement agent, and its designees, the right to receive, in the aggregate, 10% The Royalty Payment Rights Certificate obligation and Placement Agent Royalty Payment Rights Certificate obligation (the “Contingent Royalty Obligation”) was recorded as a liability at fair value as “Contingent royalty obligation” in the consolidated balance sheets as of September 30, 2022 and December 31, 2021 (see Contingent Royalty Obligation below). The fair value at inception was allocated to the royalty rights and the residual value was allocated to the preferred shares and recorded as equity. The Company amended its Certificate of Designation to modify the Royalty Payment Rights when the Company consummated its Initial Public Offering (“IPO”) on February 16, 2018, at which time the Company converted the Series A Convertible Preferred Stock into shares of the Company’s common stock and issued the Royalty Payment Rights Certificates. Pursuant to the terms of the Royalty Payment Rights Certificates, if and when the Company generates sales of the current and potential future versions of the Pure-Vu System, including disposables, parts, and services, or if the Company receives any proceeds from the licensing of the current and potential future versions of the Pure-Vu System, then the Company will pay to the holders of the Royalty Payment Rights Certificates a royalty (the “Royalty Amount”) equal to, in the aggregate, in royalty payments in any calendar year for all products: ● 3% ● 5% * Notwithstanding the foregoing, with respect to Net Sales based Royalty Amounts, (a) no Net Sales based Royalty Amount shall begin to accrue or become payable until the Company has first generated, in the aggregate, since its inception, Net Sales equal to $ 20,000 30,000 ** Notwithstanding the foregoing, with respect to Licensing Proceeds based Royalty Amounts, (a) no Licensing Proceeds based Royalty Amount shall begin to accrue or become payable until the Company has first generated, in the aggregate, since its inception, Licensing Proceeds equal to $ 3,500 30,000 The Royalty Amount will be payable up to the later of (i) the latest expiration date of the Company’s patents issued as of December 22, 2016, or (ii) the latest expiration date of any pending patents as of December 22, 2016 that have since been issued or may be issued in the future (which is currently March 2037). Following the expiration of all such patents, the holders of the Royalty Payment Rights Certificates and the holders of the Placement Agent Royalty Payment Rights Certificates will no longer be entitled to any further royalties for any period following the latest to occur of such patent expiration. On February 16, 2018, the date of the closing of the IPO, (1) the amendment to the Certificate of Designation became effective, (2) all outstanding shares of Series A Convertible Preferred Stock were converted into shares of the Company’s common stock pursuant to a mandatory conversion, and (3) the Royalty Payment Rights Certificates were issued to the former holders of the Series A Convertible Preferred Stock. Contingent Royalty Obligation The Contingent Royalty Obligation was recorded as a non-current liability at fair value in the condensed consolidated balance sheets at September 30, 2022 and December 31, 2021 in the amount of $ 1,789 1,760 34 29 35 152 Manufacturing Component Purchase Obligations The Company utilizes two outsourcing partners to manufacture its workstation and disposable portions of the Pure-Vu System, and to perform final assembly and testing of finished products. These outsourcing partners acquire components and build product based on demand information supplied by the Company. As of September 30, 2022, the Company expects to pay $ 211 Other Commitments and Contingencies The Company has a severance contingency for severance payments to its CEO, COO, and CFO in the aggregate of $ 1,428

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 10 – Related Party Transactions Shared Space Agreement In January 2020, the Company entered into a license agreement (the “Shared Space Agreement”) with Orchestra BioMed, Inc. (OBIO), formerly a greater than 5% 212 270 66 173 47 141

Share-based compensation

Share-based compensation	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Share-based compensation	Note 11 – Share-based compensation The following table sets forth total non-cash share-based compensation for the issuance of common stock, options to purchase common stock, warrants to purchase common stock, and restricted stock unit awards by operating statement classification for the three and nine months ended September 30, 2022 and 2021: Schedule of Stock-based Compensation 2022 2021 2022 2021 Three Months ended September 30, Nine Months ended September 30, 2022 2021 2022 2021 Research and development $ 96 $ 145 $ 292 $ 448 Sales and marketing 60 71 184 293 General and administrative 285 632 947 2,036 Total $ 441 $ 848 $ 1,423 $ 2,777 For the nine and three months ended September 30, 2022, the Company recorded $ 283 868 536 1,886 As of September 30, 2022, unamortized share- based compensation for stock options was $ 1,244 0.93 For the three and nine months ended September 30, 2022, the Company recorded $ 0 57 89 246 For the three and nine months ended September 30, 2022, the Company recorded $ 158 498 223 645 As of September 30, 2022, unamortized stock compensation for restricted stock units was $ 417 0.85 Stock option and warrant activity A summary of the Company’s stock option and warrant activity is as follows: Schedule of Stock option and Warrants Shares Underlying Options Weighted Average Exercise Price Shares Underlying Warrants Weighted Average Exercise Price Outstanding at December 31, 2021 307,592 $ 54.10 420,247 $ 54.76 Granted 101,497 $ 8.83 6,000 $ 10.00 Expired (6,348 ) $ 66.36 (26,670 ) $ 101.62 Cancelled - $ - (6,000 ) $ 56.60 Forfeited (3,104 ) $ 11.74 - $ - Outstanding at September 30, 2022 399,637 $ 42.76 393,577 $ 50.86 Exercisable at September 30, 2022 280,061 $ 54.25 393,577 $ 50.86 Restricted Stock Units A summary of the Company’s restricted stock unit awards activity is as follows: Schedule of Restricted Stock Unit Awards Activity Number of Shares Weighted Average Grant Date Fair Value Nonvested at December 31, 2021 25,120 $ 44.77 Granted 18,250 9.08 Vested (18,919 ) 39.87 Nonvested at September 30, 2022 24,451 $ 21.93 As of December 31, 2021, there were 3,138 Issuance of Common Stock On January 5, 2022, non-employee members of the Board of Directors were granted an aggregate of 24,458 9.60 235 58 177 58 Issuance of Warrants to Purchase Common Stock In February 2020, the Company entered into a services agreement whereby it agreed to issue warrants to purchase 6,000 56.60 6,000 10 0 26

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Reverse Stock Split	Reverse Stock Split On July 25, 2022, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-20. Shares of common stock underlying outstanding stock options and other equity instruments convertible into common stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. Accordingly, all share and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split.
Basis of presentation and principles of consolidation	Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and include the accounts of the Company and its wholly owned subsidiaries, Motus Ltd., an Israel corporation, which has operations in Tirat Carmel, Israel, and Motus Inc., a Delaware corporation, which has operations in the U.S. All inter-company accounts and transactions have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Basic and diluted net loss per share	Basic and diluted net loss per share Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year. Diluted loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive ordinary shares had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”. Potentially dilutive common shares were excluded from the calculation of diluted loss per share for all periods presented due to their anti-dilutive effect due to losses in each period. Net loss attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed preferred stock dividends declared, amortized or accumulated. The Company recorded a deemed dividend for the issuance of warrants during the three and nine months ended September 30, 2021 of $ 0 6,145
Income taxes	Income taxes The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of September 30, 2022 and December 31, 2021, the Company had a full valuation allowance against its deferred tax assets. For the three and nine months ended September 30, 2022 and 2021, the Company recorded zero income tax expense. No tax benefit has been recorded in relation to the pre-tax loss for the three and nine months ended September 30, 2022 and 2021, due to a full valuation allowance to offset any deferred tax asset related to net operating loss carry forwards attributable to the losses.
New Accounting Pronouncements- Recently Adopted	New Accounting Pronouncements- Recently Adopted In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50) Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options
Accounting Pronouncements- Not Yet Adopted	Accounting Pronouncements- Not Yet Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. In September 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for the Company to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company will continue to evaluate the effect of adopting ASU 2016-13 on the Company’s financial statements and disclosures.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Assets and Liabilities	Liabilities measured and recorded at fair value on a recurring basis consisted of the following at September 30, 2022 and December 31, 2021: Schedule of Fair Value of Financial Assets and Liabilities September 30, 2022 Level 1 Level 2 Level 3 Fair Value Liabilities Contingent royalty obligation $ - $ - $ 1,789 $ 1,789 December 31, 2021 Level 1 Level 2 Level 3 Fair Value Liabilities Contingent royalty obligation $ - $ - $ 1,760 $ 1,760
Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation	Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of a contingent royalty obligation, during the nine months ended September 30, 2022 was as follows: Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation Fair Value Measurements of Contingent Royalty Obligation (Level 3) Balance at December 31, 2021 $ 1,760 Change in estimated fair value of contingent royalty obligation 29 Balance at September 30, 2022 $ 1,789

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory at September 30, 2022 and December 31, 2021 consisted of the following: Schedule of Inventory September 30, 2022 December 31, 2021 Raw materials $ 194 $ 569 Work-in-process 120 - Finished goods 745 292 Inventory reserve (45 ) (365 ) Inventory, net $ 1,014 $ 496

Fixed assets, net (Tables)

Fixed assets, net (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets Net	Fixed assets, summarized by major category, consist of the following for the years ended: Schedule of Fixed Assets Net September 30, 2022 December 31, 2021 Office equipment $ 171 $ 171 Computers and software 319 305 Machinery 1,035 807 Lab and medical equipment 1,439 1,342 Leasehold improvements 195 193 Total 3,159 2,818 Less: accumulated depreciation and amortization (1,764 ) (1,390 ) Fixed assets, net $ 1,395 $ 1,428

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases
Schedule of Lease Cost and Supplemental Balance Sheet Information	The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows: Schedule of Lease Cost and Supplemental Balance Sheet Information 2022 2021 2022 2021 Three Months ended September 30, Nine Months ended September 30, 2022 2021 2022 2021 Lease Cost Operating lease cost, net of related party license fee $ 16 $ 36 $ 78 $ 100 Variable lease cost 30 30 90 90 Total lease cost $ 46 $ 66 $ 168 $ 190 As of September 30, As of December 31, 2022 2021 Assets Operating lease, right-of-use-asset $ 471 $ 687 Liabilities Current Operating lease liabilities $ 248 $ 307 Non-current Operating lease liabilities, net of current portion 220 385 Total lease liabilities $ 468 $ 692 Other information: Weighted average remaining lease term - operating leases 1.90 2.49 Weighted-average discount rate - operating leases 7.46 % 7.66 %

Convertible Note and Long-Ter_2

Convertible Note and Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Interest Expense for Loan	For the nine months ended September 30 , 2022, interest expense for the Loan was as follows: Schedule of Interest Expense for Loan Contractual interest expense $ 803 Amortization of debt issuance costs 195 Total interest expense $ 998 For the three months ended September 30 , 2022, interest expense for the Loan was as follows: Contractual interest expense $ 268 Amortization of debt issuance costs 70 Total interest expense $ 338
Schedule of Future Principal Payments	Future principal payments under the Convertible Note as of September 30, 2022 are as follows: Schedule of Future Principal Payments Years Ending December 31, Amount 2022 $ - 2023 - 2024 - 2025 4,000 Total future principal payments 4,000 Less unamortized debt issuance costs (123 ) Total balance $ 3,877 Future principal payments under the Long-term Debt as of September 30, 2022 are as follows: Years Ending December 31, Amount 2022 $ 702 2023 2,714 2024 2,983 2025 1,601 Total future principal payments 8,000 End of loan payments 140 Less unamortized debt issuance costs (436 ) Total term-debt balance $ 7,704 Less current portion of long-term debt (2,453 ) Total long-term debt $ 5,251

Share-based compensation (Table

Share-based compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation	The following table sets forth total non-cash share-based compensation for the issuance of common stock, options to purchase common stock, warrants to purchase common stock, and restricted stock unit awards by operating statement classification for the three and nine months ended September 30, 2022 and 2021: Schedule of Stock-based Compensation 2022 2021 2022 2021 Three Months ended September 30, Nine Months ended September 30, 2022 2021 2022 2021 Research and development $ 96 $ 145 $ 292 $ 448 Sales and marketing 60 71 184 293 General and administrative 285 632 947 2,036 Total $ 441 $ 848 $ 1,423 $ 2,777
Schedule of Stock option and Warrants	A summary of the Company’s stock option and warrant activity is as follows: Schedule of Stock option and Warrants Shares Underlying Options Weighted Average Exercise Price Shares Underlying Warrants Weighted Average Exercise Price Outstanding at December 31, 2021 307,592 $ 54.10 420,247 $ 54.76 Granted 101,497 $ 8.83 6,000 $ 10.00 Expired (6,348 ) $ 66.36 (26,670 ) $ 101.62 Cancelled - $ - (6,000 ) $ 56.60 Forfeited (3,104 ) $ 11.74 - $ - Outstanding at September 30, 2022 399,637 $ 42.76 393,577 $ 50.86 Exercisable at September 30, 2022 280,061 $ 54.25 393,577 $ 50.86
Schedule of Restricted Stock Unit Awards Activity	A summary of the Company’s restricted stock unit awards activity is as follows: Schedule of Restricted Stock Unit Awards Activity Number of Shares Weighted Average Grant Date Fair Value Nonvested at December 31, 2021 25,120 $ 44.77 Granted 18,250 9.08 Vested (18,919 ) 39.87 Nonvested at September 30, 2022 24,451 $ 21.93

Basis of Presentation and Goi_2

Basis of Presentation and Going Concern (Details Narrative) - USD ($) shares in Thousands, $ in Thousands	1 Months Ended	3 Months Ended						9 Months Ended
	Nov. 14, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from issuance of common stock								$ 4,544	$ 1,900
Payments for stock issuance cost		$ 55	$ 5	$ 111
Net cash provided by (used in) operating activities								13,429	10,505
Net income (loss) attributable to parent		4,964	$ 5,140	$ 4,811	$ 4,824	$ 4,742	$ 4,649	14,915	$ 14,215
Cash and cash equivalents		$ 13,294						$ 13,294		$ 22,563
Equity Distribution Agreement [Member] | Oppenheimer & Co. Inc [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from offering							$ 25,000
Equity Distribution Agreement [Member] | Oppenheimer & Co. Inc [Member] | Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued, shares								565
Proceeds from issuance of common stock								$ 4,400
Payments for stock issuance cost								$ 200
Equity Distribution Agreement [Member] | Oppenheimer & Co. Inc [Member] | Common Stock [Member] | Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued, shares	1,600
Proceeds from issuance of common stock	$ 5,500
Payments for stock issuance cost	$ 200

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Accounting Policies [Abstract]
Warrants deemed dividend	$ 0	$ 6,145

Schedule of Fair Value of Finan

Schedule of Fair Value of Financial Assets and Liabilities (Details) - Contigent Royalty Obligation [Member] - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent royalty obligation	$ 1,789	$ 1,760
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent royalty obligation
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent royalty obligation
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent royalty obligation	$ 1,789	$ 1,760

Schedule of Estimated Fair Valu

Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at December 31, 2021	$ 1,760
Change in estimated fair value of contingent royalty obligation	29
Balance at September 30, 2022	$ 1,789

Fair Value Measurements (Detail

Fair Value Measurements (Details Narrative)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Servicing Liability at Fair Value, Description of Other Changes in Fair Value	The Company recalculated the fair value of the liability by applying a +/- 2% change to the input variable in the discounted cash flow model; the discount rate. A 2% decrease in the discount rate would increase the liability by $130 and a 2% increase in the discount rate would decrease the liability by $119
Measurement Input, Discount Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Increase decrease in discount rate	23%	21%
Percentage relating to royalty payment	3%	3%

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 194	$ 569
Work-in-process	120
Finished goods	745	292
Inventory reserve	(45)	(365)
Inventory, net	$ 1,014	$ 496

Inventory (Details Narrative)

Inventory (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventory Write-down	$ 0	$ 186	$ 159	$ 186

Schedule of Fixed Assets Net (D

Schedule of Fixed Assets Net (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total	$ 3,159	$ 2,818
Less: accumulated depreciation and amortization	(1,764)	(1,390)
Fixed assets, net	1,395	1,428
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	171	171
Computers And Software [Member]
Property, Plant and Equipment [Line Items]
Total	319	305
Machinery [Member]
Property, Plant and Equipment [Line Items]
Total	1,035	807
Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	1,439	1,342
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total	$ 195	$ 193

Fixed assets, net (Details Narr

Fixed assets, net (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 128	$ 118	$ 381	$ 318
Impairment of fixed assets	$ 10		$ 46

Schedule of Lease Cost and Supp

Schedule of Lease Cost and Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Leases
Operating lease cost, net of related party license fee	$ 16	$ 36	$ 78	$ 100
Variable lease cost	30	30	90	90
Total lease cost	46	$ 66	168	$ 190
Operating lease, right-of-use- asset	471		471		$ 687
Operating lease liabilities, current	248		248		307
Operating lease liabilities, net of current portion	220		220		385
Total lease liabilities	$ 468		$ 468		$ 692
Weighted average remaining lease term - operating leases	1 year 10 months 24 days		1 year 10 months 24 days		2 years 5 months 26 days
Weighted-average discount rate - operating leases	7.46%		7.46%		7.66%

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Line Items]
Description of lease term option to extend			Certain operating leases include escalation clauses and some of which may include options to extend the leases for up to 3 years
Operating lease, expense	$ 46	$ 66	$ 168	$ 190
License fees	$ 66	$ 47	$ 173	$ 141
Office [Member] | Fort lauderdale [Member]
Property, Plant and Equipment [Line Items]
Operating lease, description			The term expires November 2024. The annual base rent is subject to annual increases of 2.75%
Office [Member] | ISRAEL
Property, Plant and Equipment [Line Items]
Operating lease, description			The term expires on December 31, 2022. The annual base rent is subject to increases of 4%
Operating lease expiration date			Dec. 31, 2022

Schedule of Interest Expense fo

Schedule of Interest Expense for Loan (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Debt Disclosure [Abstract]
Contractual interest expense	$ 268	$ 803
Amortization of debt issuance costs	70	195
Total interest expense	$ 338	$ 998

Schedule of Future Principal Pa

Schedule of Future Principal Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Less current portion of long-term debt	$ (2,453)	$ (431)
Total long-term debt	5,251	$ 7,121
Long-Term Debt [Member]
Debt Instrument [Line Items]
2022	702
2023	2,714
2024	2,983
2025	1,601
Total future principal payments	8,000
Less unamortized debt issuance costs	(436)
Total term-debt balance	7,704
End of loan payments	140
Less current portion of long-term debt	(2,453)
Total long-term debt	5,251
Convertible Debt [Member]
Debt Instrument [Line Items]
2022
2023
2024
2025	4,000
Total future principal payments	4,000
Less unamortized debt issuance costs	(123)
Total term-debt balance	$ 3,877

Convertible Note and Long-Ter_3

Convertible Note and Long-Term Debt (Details Narrative) - USD ($)		9 Months Ended		12 Months Ended
	Jul. 16, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments of Debt Issuance Costs			$ 437,000
Long term debt		$ 2,453,000		$ 431,000
Kreos Loan Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, periodic payment, principal	$ 12,000
Debt instrument, interest rate		7.75%
Debt instrument, convertible, conversion price		$ 28
Warrant issued to purchase common shares	9,547
Exercise price	$ 20.948
Fair Value Adjustment of Warrants		$ 165,000
Debt instrument, unamortized discount		845,000		845,000
Payments of Debt Issuance Costs		540,000
Advance payments for debt discount		274
Long term debt		140
Kreos Loan Agreement [Member] | Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, unamortized discount		$ 165,000
Kreos Loan Agreement [Member] | Tranche A [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, periodic payment, principal	$ 4,000
Kreos Loan Agreement [Member] | Tranche B [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, periodic payment, principal	5,000
Kreos Loan Agreement [Member] | Tranche C [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, periodic payment, principal	$ 3,000			$ 3,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2011	Dec. 31, 2021
Product Liability Contingency [Line Items]
Royalty received			$ 30,000		$ 1,332
LIBOR interest rate	$ 1,426		$ 1,426			$ 1,419
Royalties on revenues, percentage			4%
Net sales percentage			3%
Licensing percentage			5%
Contingent royalty obligation	1,789		$ 1,789			$ 1,760
Gain loss on change in fair value of contingent royalty obligation	$ 34	$ 35		$ 152
Gain loss on change in fair value of contingent royalty obligation			29	152
Manufacturing Costs			211
Severance Costs			1,428
Royalty [Member]
Product Liability Contingency [Line Items]
Royalties income			20,000
License [Member]
Product Liability Contingency [Line Items]
Royalty received			$ 3,500
Series A Preferred Stock [Member]
Product Liability Contingency [Line Items]
Percentage of payment amount			10%
Private Placement [Member]
Product Liability Contingency [Line Items]
Net sales percentage			3%
Licensing percentage			5%
Royalty Payment Rights Certificates [Member]
Product Liability Contingency [Line Items]
Description of royalty payment			the Royalty Payment Rights initially entitled the holders in aggregate, to a royalty in an amount of
Israeli National Authority for Technical Innovation [Member]
Product Liability Contingency [Line Items]
Royalty received			$ 0	$ 0

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jan. 31, 2021
License fee	$ 66	$ 47	$ 173	$ 141
Minimum [Member]
License fee			212
Maximum [Member]
License fee			$ 270
Shared Space Agreements [Member] | Orchestra BioMed Inc [Member]
Ownership percentage					5%

Schedule of Stock-based Compens

Schedule of Stock-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 441	$ 848	$ 1,423	$ 2,777
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	96	145	292	448
Selling, General and Administrative Expenses [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	60	71	184	293
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 285	$ 632	$ 947	$ 2,036

Schedule of Stock option and Wa

Schedule of Stock option and Warrants (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Offsetting Assets [Line Items]
Shares underlying options, forfeited	(26)
Warrant [Member]
Offsetting Assets [Line Items]
Shares Underlying Warrants, Outstanding beginning	420,247
Weighted Average Exercise Price, Outstanding beginning | $ / shares	$ 54.76
Shares Underlying Warrants, Granted	6,000
Weighted average exercise price, granted | $ / shares	$ 10
Shares underlying options, expired	(26,670)
Weighted average exercise price, expired | $ / shares	$ 101.62
Shares Underlying Warrants, Cancelled	(6,000)
Weighted average exercise price, cancelled | $ / shares	$ 56.60
Shares underlying warrants, forfeited
Weighted average exercise price, forfeited | $ / shares
Shares Underlying Warrants, Outstanding ending	393,577
Weighted average exercise price, outstanding ending | $ / shares	$ 50.86
Shares underlying warrant exercisable	393,577
Weighted average exercise price, exercisable | $ / shares	$ 50.86
Equity Option [Member]
Offsetting Assets [Line Items]
Shares underlying options, outstanding beginning	307,592
Weighted average exercise price, outstanding beginning | $ / shares	$ 54.10
Shares underlying options, granted	101,497
Weighted average exercise price, granted | $ / shares	$ 8.83
Shares underlying options, expired	(6,348)
Weighted average exercise price, expired | $ / shares	$ 66.36
Shares Underlying Warrants, Cancelled
Weighted average exercise price, cancelled | $ / shares
Shares underlying options, forfeited	(3,104)
Weighted average exercise price, forfeited | $ / shares	$ 11.74
Shares underlying options, outstanding ending	399,637
Weighted average exercise price, outstanding ending | $ / shares	$ 42.76
Shares underlying warrant exercisable	280,061
Weighted average exercise price, exercisable | $ / shares	$ 54.25

Schedule of Restricted Stock Un

Schedule of Restricted Stock Unit Awards Activity (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, nonvested beginning | shares	25,120
Aggregate weighted average grant date fair value, nonvested beginning | $ / shares	$ 44.77
Number of Shares, nonvested granted | shares	18,250
Aggregate weighted average grant date fair value, nonvested granted | $ / shares	$ 9.08
Number of Shares, nonvested vested | shares	(18,919)
Aggregate weighted average grant date fair value, nonvested vested | $ / shares	$ 39.87
Number of Shares, nonvested ending | shares	24,451
Aggregate weighted average grant date fair value, nonvested ending | $ / shares	$ 21.93

Share-based compensation (Detai

Share-based compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended						9 Months Ended		12 Months Ended
	Jan. 05, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Feb. 29, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compnesation		$ 0
Stock based compensation for stock options		441			$ 848			$ 1,423	$ 2,777
Unamortization stock compensation
Share based compnesation plan modification, incremental cost								26
Services Agreement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants exercise price											$ 10
Services Agreement [Member] | Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase of common stock											6,000
Warrants exercise price											$ 56.60
Services Agreement [Member] | Replacement Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase of common stock											6,000
NonEmployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation options, grants	24,458
Fair value of common stock	$ 9.60
Cash compensation	$ 235
Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Officers compensation		58						$ 177
Prepaid expense		58						58
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compnesation		158			223			498	645
Unamortization stock compensation								$ 417
Share based payment award equity instruments other than options outstanding weighted average remaining contractual terms								10 months 6 days
Vested and unissued restricted stock units										3,138
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compnesation		0			89			$ 57	246
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compnesation		$ 283			$ 536			868	$ 1,886
Stock based compensation for stock options								$ 1,244
Stock option weighted average								11 months 4 days
Share based compensation options, grants								101,497
Share based compnesation plan modification, incremental cost								3,104